	US 12,325,880 B2
	Identification of PDE3 modulator responsive cancers
Xiaoyun Wu, Cambridge, MA (US); and Heidi Greulich, Cambridge, MA (US)
Assigned to THE BROAD INSTITUTE, INC., Cambridge, MA (US)
Appl. No. 17/290,673
Filed by THE BROAD INSTITUTE, INC., Cambridge, MA (US)
PCT Filed Nov. 1, 2019, PCT No. PCT/US2019/059526 § 371(c)(1), (2) Date Apr. 30, 2021, PCT Pub. No. WO2020/092998, PCT Pub. Date May 7, 2020.
Claims priority of provisional application 62/901,090, filed on Sep. 16, 2019.
Claims priority of provisional application 62/754,290, filed on Nov. 1, 2018.
Prior Publication US 2021/0371935 A1, Dec. 2, 2021
Int. Cl. C12Q 1/6886 (2018.01); A61K 31/50 (2006.01); A61P 35/00 (2006.01)

CPC C12Q 1/6886 (2013.01) [A61K 31/50 (2013.01); A61P 35/00 (2018.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01)]

13 Claims

1. A method of killing or reducing the survival of a cell selected as responsive to PDE3A-SLFN12 complex formation or PDE3B-SLFN12 complex formation comprising contacting said cell with a PDE3 modulator, wherein said cell is selected as responsive to said PDE3 modulator when said cell:

(i) expresses AIP and/or TRRAP polypeptides or polynucleotides,

(ii) has increased expression of PDE3A and/or PDE3B polypeptides or polynucleotides relative to a reference, and

(iii) has increased expression of SLFN12 polypeptides or polynucleotides relative to the reference.